Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma

被引:57
作者
Natarajan, Harini [1 ]
Crowley, Andrew R. [1 ]
Butler, Savannah E. [1 ]
Xu, Shiwei [2 ]
Weiner, Joshua A. [2 ]
Bloch, Evan M. [3 ]
Littlefield, Kirsten [4 ]
Wieland-Alter, Wendy [5 ]
Connor, Ruth, I [5 ]
Wright, Peter F. [5 ]
Benner, Sarah E. [3 ]
Bonny, Tania S. [3 ]
Laeyendecker, Oliver [6 ,7 ]
Sullivan, David [4 ,6 ]
Shoham, Shmuel [6 ]
Ouinn, Thomas C. [6 ,7 ]
Larman, H. Benjamin [3 ]
Casadevall, Arturo [4 ,6 ]
Pekosz, Andrew [4 ]
Redd, Andrew D. [6 ,7 ]
Tobian, Aaron A. R. [3 ]
Ackerman, Margaret E. [1 ,2 ]
机构
[1] Dartmouth Coll, Dept Microbiol & Immunol, Geisel Sch Med Dartmouth, Hanover, NH 03755 USA
[2] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA
[3] Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD USA
[5] Dartmouth Hitchcock Med Ctr, Geisel Sch Med Dartmouth, Dept Pediat, Lebanon, NH 03766 USA
[6] Johns Hopkins Sch Med, Dept Med, Div Infect Dis, Baltimore, MD USA
[7] NIAID, Div Intramural Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA
来源
MBIO | 2021年 / 12卷 / 02期
关键词
convalescent plasma; SARS-CoV-2; COVID-19; neutralization; functional antibody response; ADCC; phagocytosis; IgA; IgG; antibody; FC ARRAY; SPIKE; PROTECTION; ASSAY;
D O I
10.1128/mBio.00765-21
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Convalescent plasma is a promising therapy for coronavirus disease 2019 (COVID-19), but the antibody characteristics that contribute to efficacy remain poorly understood. This study analyzed plasma samples from 126 eligible convales-cent blood donors in addition to 15 naive individuals, as well as an additional 20 convalescent individuals as a validation cohort. Multiplexed Fc Array binding assays and functional antibody response assays were utilized to evaluate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody composition and activ-ity. Donor convalescent plasma samples contained a range of antibody cell-and complement-media ted effector functions, indicating the diverse antiviral activity of humoral responses observed among recovered individuals. In addition to viral neutralization, convalescent plasma samples contained antibodies capable of mediating such Fc-dependent functions as complement activation, phagocytosis, and antibody-dependent cellular cytotoxicity against SARS-CoV-2. Plasma samples from a fraction of eligible donors exhibited high activity across all activities eval-uated. These polyfunctional plasma samples could be identified with high accu-racy with even single Fc Array features, whose correlation with polyfunctional ac-tivity was confirmed in the validation cohort. Collectively, these results expand understanding of the diversity of antibody-mediated antiviral functions associated with convalescent plasma, and the polyfunctional antiviral functions suggest that it could retain activity even when its neutralizing capacity is reduced by muta-tions in variant SARS-CoV-2. IMPORTANCE Convalescent plasma has been deployed globally as a treatment for COVID-19, but efficacy has been mixed. Better understanding of the antibody charac-teristics that may contribute to its antiviral effects is important for this intervention as well as offer insights into correlates of vaccine-mediated protection. Here, a sur-vey of convalescent plasma activities, including antibody neutralization and diverse effector functions, was used to define plasma samples with broad activity profiles. These polyfunctional plasma samples could be reliably identified in multiple cohorts by multiplex assay, presenting a widely deployable screening test for plasma selec-tion and investigation of vaccine-elicited responses.
引用
收藏
页数:14
相关论文
共 50 条
  • [11] Evaluation of SARS-CoV-2 antibody titers and potency for convalescent plasma donation: a brief commentary
    Wouters, Elise
    Steenhuis, Maurice
    Schrezenmeier, Hubert
    Tiberghien, Pierre
    Harvala, Heli
    Feys, Hendrik B.
    van Der Schoot, Ellen
    VOX SANGUINIS, 2021, 116 (05) : 493 - 496
  • [12] Heterologous SARS-CoV-2 IgA neutralising antibody responses in convalescent plasma
    Davis, Samantha K.
    Selva, Kevin John
    Lopez, Ester
    Haycroft, Ebene R.
    Lee, Wen Shi
    Wheatley, Adam K.
    Juno, Jennifer A.
    Adair, Amy
    Pymm, Phillip
    Redmond, Samuel J.
    Gherardin, Nicholas A.
    Godfrey, Dale, I
    Tham, Wai-Hong
    Kent, Stephen J.
    Chung, Amy W.
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2022, 11 (10)
  • [13] Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals
    Butler, Savannah E.
    Crowley, Andrew R.
    Natarajan, Harini
    Xu, Shiwei
    Weiner, Joshua A.
    Bobak, Carly A.
    Mattox, Daniel E.
    Lee, Jiwon
    Wieland-Alter, Wendy
    Connor, Ruth, I
    Wright, Peter F.
    Ackerman, Margaret E.
    FRONTIERS IN IMMUNOLOGY, 2021, 11
  • [14] Comparison of Serological Assays for the Detection of SARS-CoV-2 Antibodies
    James, Joe
    Rhodes, Shelley
    Ross, Craig S.
    Skinner, Paul
    Smith, Samuel P.
    Shipley, Rebecca
    Warren, Caroline J.
    Goharriz, Hooman
    McElhinney, Lorraine M.
    Temperton, Nigel
    Wright, Edward
    Fooks, Anthony R.
    Clark, Tristan W.
    Brookes, Sharon M.
    Brown, Ian H.
    Banyard, Ashley C.
    VIRUSES-BASEL, 2021, 13 (04):
  • [15] SARS-COV-2 Triggers the Development of Class I and Class II HLA Antibodies in Recovered Convalescent Plasma Donors
    Dada, Ashraf
    Elhassan, Khalid
    Bawayan, Rayan Mohammed
    Albishi, Ghadeer
    Hefni, Lama
    Bassi, Sawsan
    Sobahy, Turki
    Cupler, Edward
    AlBaz, Nabeela
    Wali, Ghassan
    Alraddadi, Basem
    Alshukairi, Abeer N.
    INTERVIROLOGY, 2022, 65 (04) : 230 - 235
  • [16] SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
    Focosi, Daniele
    Tuccori, Marco
    Baj, Andreina
    Maggi, Fabrizio
    VIRUSES-BASEL, 2021, 13 (07):
  • [17] Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
    Maeda, Kenji
    Higashi-Kuwata, Nobuyo
    Kinoshita, Noriko
    Kutsuna, Satoshi
    Tsuchiya, Kiyoto
    Hattori, Shin-ichiro
    Matsuda, Kouki
    Takamatsu, Yuki
    Gatanaga, Hiroyuki
    Oka, Shinichi
    Sugiyama, Haruhito
    Ohmagari, Norio
    Mitsuya, Hiroaki
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [18] The Evidence for High-Titer Convalescent Plasma in SARS-CoV-2
    David L. Fisher
    Pavel Alin
    Stephen Malnick
    SN Comprehensive Clinical Medicine, 2021, 3 (3) : 790 - 792
  • [19] Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters
    Wouters, Elise
    Verbrugghe, Caro
    Abdelnabi, Rana
    Devloo, Rosalie
    De Clippel, Dorien
    Jochmans, Dirk
    De Bleser, Dominique
    Weynand, Birgit
    Compernolle, Veerle
    Neyts, Johan
    Feys, Hendrik B.
    EBIOMEDICINE, 2023, 92
  • [20] Novel protocol for selection of SARS-CoV-2 convalescent plasma donors
    Ostojic, Gordana
    Supic, Gordana
    Karlicic, Vukoica
    Karlicic, Marija
    Ristanovic, Elizabeta
    Kovacevic, Milan
    Abazovic, Dzihan
    Gojkov, Dragana
    Stanojevic, Ivan
    Vukosavljevic, Miroslav
    Vojvodic, Danilo
    VOJNOSANITETSKI PREGLED, 2022, 79 (05) : 496 - 502